Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 3
Submit an article Journal homepage
1,121
Views
49
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies

AnnaLynn M. WilliamsWilmot Cancer Institute, University of Rochester, Rochester, NY, USA; View further author information
,
Andrea M. BaranWilmot Cancer Institute, University of Rochester, Rochester, NY, USA; View further author information
,
Philip J. MeachamWilmot Cancer Institute, University of Rochester, Rochester, NY, USA; View further author information
,
Megan M. FeldmanWilmot Cancer Institute, University of Rochester, Rochester, NY, USA; View further author information
,
Hugo E. ValenciaDepartment of Internal Medicine, University of Rochester, Rochester, NY, USA; View further author information
,
Catherine Newsom-StewartWilmot Cancer Institute, University of Rochester, Rochester, NY, USA; View further author information
,
Nealansh GuptaWilmot Cancer Institute, University of Rochester, Rochester, NY, USA; View further author information
,
Michelle C. JanelsinsWilmot Cancer Institute, University of Rochester, Rochester, NY, USA; ;Department of Surgery, University of Rochester, Rochester, NY, USAView further author information
,
Paul M. BarrWilmot Cancer Institute, University of Rochester, Rochester, NY, USA; View further author information
&
Clive S. ZentWilmot Cancer Institute, University of Rochester, Rochester, NY, USA; Correspondence[email protected]
View further author information
 show all
Pages 625-632 | Received 01 May 2017, Accepted 21 Jun 2017, Published online: 11 Jul 2017

References

  • Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66:443–459.
  • Dores GM, Anderson WF, Curtis RE, et al. Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol. 2007;139:809–819.
  • DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64:252–271.
  • Forconi F, Moss P. Perturbation of the normal immune system in patients with CLL. Blood. 2015;126:573–581.
  • Sun C, Tian X, Lee YS, et al. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood. 2015;126:2213–2219.
  • Niemann CU, Herman SE, Maric I, et al. Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib–Findings from an Investigator-Initiated Phase II Study. Clin Cancer Res. 2016;22:1572–1582.
  • Moreira J, Rabe KG, Cerhan JR, et al. Infectious complications among individuals with clinical monoclonal B-cell lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controls. Leukemia. 2013;27:136–141.
  • Morrison VA, Rai KR, Peterson BL, et al. Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. JCO. 2001;19:3611–3621.
  • Hensel M, Kornacker M, Yammeni S, et al. Disease activity and pretreatment, rather than hypogammaglobulinaemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukaemia. Br J Haematol. 2003;122:600–606.
  • Anaissie EJ, Kontoyiannis DP, O'Brien S, et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med. 1998;129:559–566.
  • Morrison VA. Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches. Best Pract Res Clin Haematol. 2010;23:145–153.
  • Morrison VA. Infections in patients with leukemia and lymphoma. Cancer Treat Res. 2014;161:319–349.
  • NCI. 2010. Common Terminology Criteria for Adverse Events (CTCAE) v4. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm
  • Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377–381.
  • Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910–1916.
  • Hallek M. Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment. Am J Hematol. 2013;88:803–816.
  • Visentin A, Compagno N, Cinetto F, et al. Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy. Haematologica. 2015;100:e515–e518.
  • Francis S, Karanth M, Pratt G, et al. The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia. Cancer. 2006;107:1023–1033.
  • Dasanu CA. Intrinsic and treatment-related immune alterations in chronic lymphocytic leukaemia and their impact for clinical practice. Expert Opin Pharmacother. 2008;9:1481–1494.
  • Morrison VA. Management of infectious complications in patients with chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2007;2007:332–338.
  • Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125:2497–2506.
  • Riches JC, Gribben JG. Understanding the immunodeficiency in chronic lymphocytic leukemia: potential clinical implications. Hematol Oncol Clin North Am. 2013;27:207–235.
  • Ysebaert L, Gross E, Kuhlein E, et al. Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy. Leukemia. 2010;24:1310–1316.
  • Ahn IE, Jerussi T, Farooqui M, et al. Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib. Blood. 2016;128:1940–1943.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.